BACKGROUND: Cisplatin-based adjuvant treatment of non-small cell lung cancer (NSCLC) has become standard, thanks to the studies that have shown a significant survival advantage. The identification of patients who could benefit from this adjuvant treatment would allow ineffective and toxic administrations to be avoided. Immunohistochemical expression of the excision repair cross-complementation group (ERCC)-1 protein has been associated with response to platinum-based chemotherapy in patients with NSCLC, and some polymorphisms of the genes involved in DNA repair have been shown to be associated with survival in advanced NSCLC. OBJECTIVE: The aim of our study was to evaluate the progression-free survival and tolerability of adjuvant treatment with platinum-based chemotherapy in patients with NSCLC, according to common DNA repair gene polymorphisms and ERCC1 expression. METHODS: We investigated the association of three DNA repair gene polymorphisms - Asn118Asn in ERCC1 (rs11615), Lys751Gln in ERCC2 (rs13181), and Asp1104His in ERCC5 (rs17655) - with the progression-free survival of 85 patients treated with platinum-based chemotherapy after surgery for NSCLC. RESULTS: We did not find significant associations between any of these polymorphisms and progression-free survival, nor did we observe any difference in progression-free survival according to ERCC1 expression. CONCLUSION: The previously reported impact of DNA repair gene polymorphisms on platinum-based chemotherapy treatment of advanced NSCLC was not observed in our study in the adjuvant setting.
BACKGROUND:Cisplatin-based adjuvant treatment of non-small cell lung cancer (NSCLC) has become standard, thanks to the studies that have shown a significant survival advantage. The identification of patients who could benefit from this adjuvant treatment would allow ineffective and toxic administrations to be avoided. Immunohistochemical expression of the excision repair cross-complementation group (ERCC)-1 protein has been associated with response to platinum-based chemotherapy in patients with NSCLC, and some polymorphisms of the genes involved in DNA repair have been shown to be associated with survival in advanced NSCLC. OBJECTIVE: The aim of our study was to evaluate the progression-free survival and tolerability of adjuvant treatment with platinum-based chemotherapy in patients with NSCLC, according to common DNA repair gene polymorphisms and ERCC1 expression. METHODS: We investigated the association of three DNA repair gene polymorphisms - Asn118Asn in ERCC1 (rs11615), Lys751Gln in ERCC2 (rs13181), and Asp1104His in ERCC5 (rs17655) - with the progression-free survival of 85 patients treated with platinum-based chemotherapy after surgery for NSCLC. RESULTS: We did not find significant associations between any of these polymorphisms and progression-free survival, nor did we observe any difference in progression-free survival according to ERCC1 expression. CONCLUSION: The previously reported impact of DNA repair gene polymorphisms on platinum-based chemotherapy treatment of advanced NSCLC was not observed in our study in the adjuvant setting.
Authors: Richard Booton; Tim Ward; Jim Heighway; Pat Taylor; Fiona Power; Linda Ashcroft; Julie Morris; Nicholas Thatcher Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Y Takebayashi; K Nakayama; A Kanzaki; H Miyashita; O Ogura; S Mori; M Mutoh; K Miyazaki; M Fukumoto; Y Pommier Journal: Cancer Lett Date: 2001-12-28 Impact factor: 8.679
Authors: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245
Authors: F Toffalorio; E Giovannetti; T De Pas; D Radice; G Pelosi; M Manzotti; D Minocci; L Spaggiari; G Spitaleri; C Noberasco; C Catania; S Boselli; R Danesi; F de Braud Journal: Pharmacogenomics J Date: 2009-11-10 Impact factor: 3.550
Authors: D Isla; C Sarries; R Rosell; G Alonso; M Domine; M Taron; G Lopez-Vivanco; C Camps; M Botia; L Nuñez; M Sanchez-Ronco; J J Sanchez; M Lopez-Brea; I Barneto; A Paredes; B Medina; A Artal; P Lianes Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Aristea Kalikaki; Maria Kanaki; Helen Vassalou; John Souglakos; Alexandra Voutsina; Vassilis Georgoulias; Dimitris Mavroudis Journal: Clin Lung Cancer Date: 2009-03 Impact factor: 4.785
Authors: Nikhil R Bhagwat; Vera Y Roginskaya; Marie B Acquafondata; Rajiv Dhir; Richard D Wood; Laura J Niedernhofer Journal: Cancer Res Date: 2009-09-01 Impact factor: 12.701
Authors: Xiaolu Zhang; Erin L Crawford; Thomas M Blomquist; Sadik A Khuder; Jiyoun Yeo; Albert M Levin; James C Willey Journal: Physiol Genomics Date: 2016-05-27 Impact factor: 3.107
Authors: Caglayan Geredeli; Mehmet Artac; Selman Yildirim; Ali Inal; Isa Dede; Tunc Guler; Melih Cem Boruban; Lokman Koral; Mustafa Karaagac; Ayse Gul Zamani; Tamer Altinok; Olgun Aribas; Hakan Bozcuk; Ahmet Demirkazik Journal: Tumour Biol Date: 2015-01-18